Beer M, Richardson A, Poat J, Iversen L L, Stahl S M
Merck Sharp & Dohme Research Laboratories, Neuroscience Research Centre, Terlings Park, Harlow, Essex, U.K.
Biochem Pharmacol. 1988 Mar 15;37(6):1145-51. doi: 10.1016/0006-2952(88)90523-0.
A radioreceptor binding assay was developed to determine the selectivity of beta-adrenoceptor agents in rat brain. This was achieved by using the highly selective unlabelled antagonists CGP 20712A and ICI 118-551 to block beta 1- or beta 2-sub-populations respectively in rat cerebral cortex membranes. This permitted the selective labelling of beta-adrenoceptors with the antagonist (-)-[125I]pindolol. Using this method, compounds could be routinely screened and selectivity profiles for binding in the CNS determined with a high degree of sensitivity and resolution.
开发了一种放射受体结合试验来测定β-肾上腺素受体药物在大鼠脑中的选择性。这是通过使用高选择性未标记拮抗剂CGP 20712A和ICI 118-551分别阻断大鼠大脑皮层膜中的β1或β2亚群来实现的。这使得可以用拮抗剂(-)-[125I]吲哚洛尔对β-肾上腺素受体进行选择性标记。使用这种方法,可以常规筛选化合物,并以高度的灵敏度和分辨率确定其在中枢神经系统中的结合选择性谱。